

Sebastian H Unizony

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6671451/publications.pdf>

Version: 2024-02-01

38
papers

3,049
citations

361413

20
h-index

526287

27
g-index

38
all docs

38
docs citations

38
times ranked

5262
citing authors

#	ARTICLE	IF	CITATIONS
1	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2022, 61, 2915-2922.	1.9	24
2	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 653-661.	0.9	49
3	The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial. <i>Rheumatology and Therapy</i> , 2022, 9, 497-508.	2.3	1
4	Case 3-2021: A 48-Year-Old Man with Transient Vision Loss. <i>New England Journal of Medicine</i> , 2021, 384, 363-372.	27.0	0
5	Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. <i>Arthritis Research and Therapy</i> , 2021, 23, 8.	3.5	33
6	Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 469-476.	3.4	23
7	Treatment failure in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1467-1474.	0.9	20
8	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2333-2344.	27.0	1,102
9	A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. <i>Rheumatology and Therapy</i> , 2020, 7, 793-810.	2.3	30
10	351.â€fEFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL. <i>Rheumatology</i> , 2019, 58, .	1.9	0
11	Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database. <i>Rheumatology and Therapy</i> , 2019, 6, 599-610.	2.3	14
12	358.â€fRISK FACTORS FOR TREATMENT FAILURE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE VERSUS PREDNISONE ALONE. <i>Rheumatology</i> , 2019, 58, .	1.9	0
13	O26â€fEffects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in the GiACTA trial. <i>Rheumatology</i> , 2019, 58, .	1.9	0
14	272â€fAcute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial. <i>Rheumatology</i> , 2019, 58, .	1.9	0
15	274.â€fCLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN REAL-WORLD CLINICAL PRACTICE. <i>Rheumatology</i> , 2019, 58, .	1.9	0
16	FRI0292â€f...A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIRUKUMAB IN THE TREATMENT OF PATIENTS WITH GIANT CELL ARTERITIS. , 2019, , .		0
17	SAT0248â€f...CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN REAL-WORLD CLINICAL PRACTICE. , 2019, , .		0
18	FRI0262â€f...CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS WITH POLYMYALGIA SYMPTOMS ONLY VS CRANIAL SYMPTOMS ONLY TREATED WITH TOCILIZUMAB OR PLACEBO IN THE GIACTA TRIAL. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	THU0321â€¦CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA SYMPTOMS TREATED WITH TOCILIZUMAB IN ROUTINE CLINICAL PRACTICE. , 2019, , .		0
20	FRI0261â€¦RISK FACTORS FOR TREATMENT FAILURE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE VERSUS PREDNISONE ALONE. , 2019, , .		3
21	Pearls & Oysters: Neuro-Sweet disease presenting as ischemic stroke and aseptic meningitis. <i>Neurology</i> , 2018, 91, e2197-e2199.	1.1	3
22	IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 551-558.	0.8	3
23	An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 898-905.	0.9	76
24	Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 176-184.	5.6	22
25	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017, 377, 317-328.	27.0	974
26	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 657-664.	3.4	62
27	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 1004-1010.	3.4	11
28	Nationwide Trends in Hospitalizations and Inâ€“Hospital Mortality in Granulomatosis With Polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2017, 69, 915-921.	3.4	32
29	Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. <i>RMD Open</i> , 2017, 3, e000570.	3.8	33
30	Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature. <i>Clinical Rheumatology</i> , 2016, 35, 251-258.	2.2	8
31	Novel compound heterozygous variants in <i>CECR1</i> gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2. <i>Rheumatology</i> , 2016, 55, 1145-1147.	1.9	22
32	Myeloperoxidaseâ€“Antineutrophil Cytoplasmic Antibody (ANCA)â€“Positive and ANCAâ€“Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. <i>Arthritis and Rheumatology</i> , 2016, 68, 2945-2952.	5.6	75
33	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1166-1169.	0.9	196
34	Improved survival in granulomatosis with polyangiitis: A general population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 483-489.	3.4	55
35	Surgical site infection in hand surgery. <i>International Orthopaedics</i> , 2015, 39, 2191-2198.	1.9	37
36	Challenging Mimickers of Primary Systemic Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 141-160.	1.9	20

#	ARTICLE	IF	CITATIONS
37	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis and Rheumatology, 2015, 67, 535-544.	5.6	25
38	Design of the Tocilizumab in Giant Cell Arteritis Trial. International Journal of Rheumatology, 2013, 2013, 1-10.	1.6	96